Microbiome Therapeutics Market - Top Companies and Manufacturers

Companies Dominating the Microbiome Therapeutics Landscape

YSOPIA Bioscience
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis

4D pharma plc
Enterome
BiomX Inc.
Ferring International Center S.A.
Vedanta Biosciences, Inc.
Seres Therapeutics, Inc.
Assembly Biosciences, Inc.
Synlogic
Finch Therapeutics Group, Inc.

Browse Key Market Insights with Data Illustration:

Microbiome Therapeutics Market Size, Growth Forecasts 2023-2035

In the News

Enterome has introduced the world's first clinical data with EO2401, its first-in-class off-the-shelf OncoMimics therapeutic cancer vaccine, at the American Society of Clinical Oncology (ASCO) Annual Meeting.
Ferring International Center S.A. has received approval from the U.S. FDA for REBYOTA (fecal microbiota, live-jslm). It is a novel first-in-class microbiota-based live biotherapeutic denoted for the inhibition of recurrence of Clostridioides difficile infection (CDI) in individuals of 18 years of age and older, following antibiotic treatment for recurrent CDI.

Frequently Asked Questions (FAQ)

Rise in the investments of microbiome modulators, worldwide growing prevalence of diabetes, and an increase in the development of novel microbiome are the major factors driving the market growth.

The market is anticipated to attain a CAGR of 24% over the forecast period, i.e., 2023-2035.

Risk of failure of the concerned research projects, and stringent regulatory guidelines imposed by the government of nations are estimated to be the growth hindering factors for the market expansion.

The market in the North American region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.

The major players in the market are YSOPIA Bioscience, 4D pharma plc, Enterome, BiomX Inc., Ferring International Center S.A., Vedanta Biosciences, Inc., Seres Therapeutics, Inc., Finch Therapeutics Group, Inc., and others.

The company profiles are selected based on the revenues generated from segments, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.

The market is segmented by type, application, product, and by region.

The diabetes segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.

Microbiome Therapeutics Market - Top Companies and Manufacturers

Companies Dominating the Microbiome Therapeutics Landscape

Browse Key Market Insights with Data Illustration:

In the News

Frequently Asked Questions (FAQ)

What are the major factors driving the growth of the Microbiome Therapeutics market?

What would be the CAGR of Microbiome Therapeutics market over the forecast period?

What are the challenges affecting the Microbiome Therapeutics market growth?

Which region will provide more business opportunities for growth of Microbiome Therapeutics market in future?

Who are the major players dominating the Microbiome Therapeutics market?

How are the company profiles selected?

What are the segments in the microbiome therapeutics market?

Which segment captures the largest market size in the application segment in the microbiome therapeutics market?